NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $1.82 billion. The enterprise value is $1.54 billion.
Important Dates
The last earnings date was Wednesday, October 30, 2024, before market open.
| Earnings Date | Oct 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 108.20 million shares outstanding. The number of shares has increased by 1.49% in one year.
| Current Share Class | 108.20M |
| Shares Outstanding | 108.20M |
| Shares Change (YoY) | +1.49% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 8.95% |
| Owned by Institutions (%) | 87.50% |
| Float | 98.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.14 |
| Forward PS | 2.99 |
| PB Ratio | 5.05 |
| P/TBV Ratio | 5.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 1.87.
| Current Ratio | 1.49 |
| Quick Ratio | 1.43 |
| Debt / Equity | 1.87 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.55 |
Financial Efficiency
Return on equity (ROE) is -39.70% and return on invested capital (ROIC) is -9.29%.
| Return on Equity (ROE) | -39.70% |
| Return on Assets (ROA) | -7.93% |
| Return on Capital (ROIC) | -9.29% |
| Revenue Per Employee | $397,617 |
| Profits Per Employee | -$103,086 |
| Employee Count | 1,453 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 3.57 |
Taxes
In the past 12 months, NovoCure has paid $35.29 million in taxes.
| Income Tax | 35.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.30% in the last 52 weeks. The beta is 0.70, so NovoCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +36.30% |
| 50-Day Moving Average | 16.52 |
| 200-Day Moving Average | 17.11 |
| Relative Strength Index (RSI) | 50.73 |
| Average Volume (20 Days) | 909,770 |
Short Selling Information
The latest short interest is 5.96 million, so 5.50% of the outstanding shares have been sold short.
| Short Interest | 5.96M |
| Short Previous Month | 5.78M |
| Short % of Shares Out | 5.50% |
| Short % of Float | 6.05% |
| Short Ratio (days to cover) | 4.79 |
Income Statement
In the last 12 months, NovoCure had revenue of $577.74 million and -$149.78 million in losses. Loss per share was -$1.39.
| Revenue | 577.74M |
| Gross Profit | 442.26M |
| Operating Income | -150.19M |
| Pretax Income | -141.13M |
| Net Income | -149.78M |
| EBITDA | -140.61M |
| EBIT | -150.19M |
| Loss Per Share | -$1.39 |
Full Income StatementBalance Sheet
The company has $959.90 million in cash and $675.63 million in debt, giving a net cash position of $284.27 million or $2.63 per share.
| Cash & Cash Equivalents | 959.90M |
| Total Debt | 675.63M |
| Net Cash | 284.27M |
| Net Cash Per Share | $2.63 |
| Equity (Book Value) | 360.78M |
| Book Value Per Share | 3.34 |
| Working Capital | 360.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$37.48 million and capital expenditures -$40.73 million, giving a free cash flow of -$78.21 million.
| Operating Cash Flow | -37.48M |
| Capital Expenditures | -40.73M |
| Free Cash Flow | -78.21M |
| FCF Per Share | -$0.72 |
Full Cash Flow StatementMargins
Gross margin is 76.55%, with operating and profit margins of -26.00% and -25.93%.
| Gross Margin | 76.55% |
| Operating Margin | -26.00% |
| Pretax Margin | -19.82% |
| Profit Margin | -25.93% |
| EBITDA Margin | -24.34% |
| EBIT Margin | -26.00% |
| FCF Margin | -19.00% |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.49% |
| Shareholder Yield | -1.49% |
| Earnings Yield | -8.21% |
| FCF Yield | -4.29% |
Dividend DetailsAnalyst Forecast
The average price target for NovoCure is $26.60, which is 57.77% higher than the current price. The consensus rating is "Buy".
| Price Target | $26.60 |
| Price Target Difference | 57.77% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 13.60% |
| EPS Growth Forecast (5Y) | -14.77% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.37 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.37 |
| Piotroski F-Score | 4 |